TY - JOUR T1 - Time to say goodbye to minocycline? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 49 LP - 49 DO - 10.1136/dtb.2013.5.0176 VL - 51 IS - 5 A2 - , Y1 - 2013/05/01 UR - http://dtb.bmj.com/content/51/5/49.abstract N2 - Minocycline has been licensed for over 35 years for a wide range of bacterial infections (a Summary of Product Characteristics [SPC] lists 16 indications) including respiratory, genitourinary and skin conditions.1,2 However, much of its popularity has been for its use in treating acne. Minocycline was associated with claims that it was “more effective, less likely to cause bacterial resistance and easier to take than other tetracyclines”.3 In addition, the availability of an adherence-friendly, once-daily, modified-release preparation and a lack of restriction when taken with food or ‘moderate amounts of milk’, quickly made it a favourite with general practitioners and patients. It became particularly popular for use for teenagers … ER -